Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

NCT05990725 is registered in ClinicalTrials.gov with Almirall, S.A. as lead sponsor.

NCT NCT05990725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05990725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
Lead sponsor
Almirall, S.A.
Phase
Phase 3
Overall status
Completed
Start date
November 20, 2023
Completion date
June 25, 2025
Enrollment
260 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis, eczema